195 related articles for article (PubMed ID: 11205215)
1. Beta-2-microglobulin (beta 2M) as a tumor marker in nasopharyngeal carcinoma.
Lee JK; Tsai SC; Hsieh JF; Ho YJ; Sun SS; Kao CH
Anticancer Res; 2000; 20(6C):4765-8. PubMed ID: 11205215
[TBL] [Abstract][Full Text] [Related]
2. Tissue polypeptide specific antigen (TPS) as a tumor marker in nasopharyngeal carcinoma.
Sun SS; Hsieh JF; Tsai SC; Ho YJ; Kao CH
Anticancer Res; 2000; 20(6C):4661-3. PubMed ID: 11205197
[TBL] [Abstract][Full Text] [Related]
3. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma.
Tai CJ; Liu FY; Liang JA; Yang SN; Tsai MH; Kao CH
Anticancer Res; 2002; 22(6B):3793-6. PubMed ID: 12552995
[TBL] [Abstract][Full Text] [Related]
4. The value of CYFRA 21-1, a new tumor marker, in nasopharyngeal carcinoma.
Lin WY; Yen TC; Cheng KY; Wang SJ
Neoplasma; 1998; 45(1):21-4. PubMed ID: 9604997
[TBL] [Abstract][Full Text] [Related]
5. Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy.
Ma BB; Leungm SF; Hui EP; Mo F; Kwan WH; Zee B; Yuen J; Chan AT
Cancer; 2004 Aug; 101(4):776-81. PubMed ID: 15305409
[TBL] [Abstract][Full Text] [Related]
6. Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis.
Wei YS; Zheng YH; Liang WB; Zhang JZ; Yang ZH; Lv ML; Jia J; Zhang L
Cancer; 2008 Feb; 112(3):544-51. PubMed ID: 18085639
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic significance of plasma matrix metalloproteinase-2 and -9 levels in patients with undifferentiated nasopharyngeal carcinoma.
Wong TS; Kwong DL; Sham JS; Wei WI; Kwong YL; Yuen AP
Eur J Surg Oncol; 2004 Jun; 30(5):560-4. PubMed ID: 15135487
[TBL] [Abstract][Full Text] [Related]
8. [Serum beta 2-microglobulin determination in nasopharyngeal carcinoma patients. An analysis of 139 cases].
Luo ZM
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1992; 27(4):239-40, 256. PubMed ID: 1298313
[TBL] [Abstract][Full Text] [Related]
9. A prospective study of p53 expression and its correlation with clinical response of radiotherapy in nasopharyngeal carcinoma.
Ho KY; Kuo WR; Chai CY; Tsai SM; Sheu SH; Wu SC; Juan KH
Laryngoscope; 2001 Jan; 111(1):131-6. PubMed ID: 11192881
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of Survivin and Livin in nasopharyngeal carcinoma.
Xiang Y; Yao H; Wang S; Hong M; He J; Cao S; Min H; Song E; Guo X
Laryngoscope; 2006 Jan; 116(1):126-30. PubMed ID: 16481824
[TBL] [Abstract][Full Text] [Related]
11. Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of cystatin A for predicting nodal stage and poor prognosis.
Chang KP; Wu CC; Chen HC; Chen SJ; Peng PH; Tsang NM; Lee LY; Liu SC; Liang Y; Lee YS; Hao SP; Chang YS; Yu JS
Proteomics; 2010 Jul; 10(14):2644-60. PubMed ID: 20461718
[TBL] [Abstract][Full Text] [Related]
12. [Quantitative changes in the immunoglobulin G subclass system--a reliable tumor marker in squamous epithelial carcinoma in the area of the head-neck].
Anderhuber W; Steinschifter W; Gotschuli A; Schauenstein E; Schauenstein K
Laryngorhinootologie; 1998 Oct; 77(10):564-8. PubMed ID: 9842520
[TBL] [Abstract][Full Text] [Related]
13. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma.
Leung SF; Zee B; Ma BB; Hui EP; Mo F; Lai M; Chan KC; Chan LY; Kwan WH; Lo YM; Chan AT
J Clin Oncol; 2006 Dec; 24(34):5414-8. PubMed ID: 17135642
[TBL] [Abstract][Full Text] [Related]
14. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma.
Li YH; Hu CF; Shao Q; Huang MY; Hou JH; Xie D; Zeng YX; Shao JY
J Transl Med; 2008 Jan; 6():1. PubMed ID: 18171482
[TBL] [Abstract][Full Text] [Related]
15. Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma.
Wong TS; Kwong DL; Sham J; Wei WI; Kwong YL; Yuen AP
Eur J Surg Oncol; 2005 Jun; 31(5):555-8. PubMed ID: 15922893
[TBL] [Abstract][Full Text] [Related]
16. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
17. Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival.
Liao WT; Song LB; Zhang HZ; Zhang X; Zhang L; Liu WL; Feng Y; Guo BH; Mai HQ; Cao SM; Li MZ; Qin HD; Zeng YX; Zeng MS
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):508-14. PubMed ID: 17255272
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of measuring levels of tumor necrosis factor-alpha and soluble interleukin-2 receptor in nasopharyngeal carcinoma.
Hsiao SH; Lee MS; Lin HY; Su YC; Ho HC; Hwang JH; Lee CC; Hung SK
Acta Otolaryngol; 2009 Dec; 129(12):1519-23. PubMed ID: 19922107
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of nasopharyngeal carcinoma staging by magnetic resonance imaging.
Lau KY; Kan WK; Sze WM; Lee AW; Yau TK; Tan LT; Chan PO
Australas Radiol; 2004 Mar; 48(1):14-6. PubMed ID: 15027914
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
